Stock TRAW TRAWS PHARMA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Traws Pharma, Inc.

Equities

TRAW

US68232V8019

Real-time Estimate Cboe BZX
Other stock markets
 12:59:41 2024-06-12 pm EDT 		5-day change 1st Jan Change
0.581 USD -11.43% Intraday chart for Traws Pharma, Inc. +3.16% -20.86%
May. 15 Traws Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
May. 07 Traws Pharma Completes First Cohort Dosed in Phase 1 Trial for COVID Therapy CI

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Traws Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Traws Pharma Completes First Cohort Dosed in Phase 1 Trial for COVID Therapy
CI
Onconova Therapeutics Shares Drop; Company to Merge With Trawsfynydd Therapeutics
MT
Onconova Therapeutics, Inc. completed the acquisition of Trawsfynydd Therapeutics, Inc.
CI
Onconova Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Onconova TherapeuticsNarazaciclib Ash Poster Highlights Activity in Treatment Resistant Mantle Cell Lymphoma
CI
Onconova Therapeutics? Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i?s
CI
Earnings Flash (ONTX) ONCONOVA THERAPEUTICS Posts Q3 Revenue $57,000
MT
Onconova Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Earnings Flash (ONTX) ONCONOVA THERAPEUTICS Reports Q2 Revenue $57,000, vs. Street Est of $0.07M
MT
Onconova Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
Onconova Therapeutics, Inc. Presents Preclinical Data on Narazaciclib at the 17Th International Conference on Malignant Lymphoma
CI
Onconova Therapeutics Announces Dosing of First Participant in Investigator-Sponsored Phase 2 Trial of Rigosertib Plus Pembrolizumab in Metastatic Melanoma Patients Refractory to Immune Checkpoint Blockade
CI
Onconova Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Onconova Therapeutics Doses First Patient in Phase 1/2a Trial of Narazaciclib Combined with Letrozole in Endometrial Cancer
CI
Onconova Therapeutics, Inc. and Pangea Biomed Enter into Research Collaboration to Identify Biomarkers of Response to Rigosertib
CI
Onconova Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
Onconova Therapeutics, Inc. Presents Preclinical Data Characterizing Rigosertib’s Mechanisms
CI
Onconova Therapeutics, Inc. Announces Additional Clinical Data Demonstrating Rigosertib’s Monotherapy Activity in RDEB-Associated Squamous Cell Carcinoma
CI
Onconova Therapeutics Discloses Plan for Phase 1/2a Cancer Trial
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. TRAW Stock
  4. News Traws Pharma, Inc.
  5. Highlights